title: Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia.
authors.affiliation: Pharmacy Department, Warren G. Magnuson Clinical Center, National Cancer Institute, Bethesda, MD 20892.
authors.forename: P F
authors.initials: PF
authors.lastname: Jarosinski
authors.forename: J A
authors.initials: JA
authors.lastname: Moscow
authors.forename: M S
authors.initials: MS
authors.lastname: Alexander
authors.forename: L J
authors.initials: LJ
authors.lastname: Lesko
authors.forename: F M
authors.initials: FM
authors.lastname: Balis
authors.forename: D G
authors.initials: DG
authors.lastname: Poplack
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D002648:Child; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007945:Leukemia, Lymphoid / Q000150:complications / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000494:pharmacology; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008727:Methotrexate / Q000494:pharmacology; D010672:Phenytoin / Q000493:pharmacokinetics*; D011241:Prednisone / Q000494:pharmacology; D014750:Vincristine / Q000494:pharmacology
chemical_list: D014750:Vincristine; D010672:Phenytoin; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate